Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

Ashina, M; Lipton, RB; Ailani, J; Versijpt, J; Sacco, S; Mitsikostas, DD; Christoffersen, CL; Sperling, B; Ettrup, A

Ashina, M (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Danish Headache Ctr, Dept Neurol,Rigshosp Glostrup, Valdemar Hansen Vej 5, DK-2600 Glostrup, Denmark.

EUROPEAN JOURNAL OF NEUROLOGY, 2023; ():

Abstract

Background and purpose: Eptinezumab reduced monthly migraine days more than placebo in the DELIVER study, a clinical trial with patients with difficul......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索